Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome
Portfolio Pulse from
Humanetics has chosen Lifecore Biomedical to provide CDMO services for the development of BIO 300, a radioprotective agent aimed at preventing Acute Radiation Syndrome. This project is funded by the Department of Defense as a medical countermeasure.
March 17, 2025 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lifecore Biomedical has been selected by Humanetics to provide CDMO services for the development of BIO 300, a radioprotective agent. This partnership is backed by the Department of Defense funding.
The partnership with Humanetics and the backing of the Department of Defense funding is likely to positively impact Lifecore Biomedical's stock in the short term. The development of BIO 300 as a radioprotective agent could enhance Lifecore's reputation and financial performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80